- Citations, last 5 years
- 4
- Works, last 5 years
- 4
- h-index
- 147
- Scientists listed
- 0
- Grants since 2016
- 7
Grants received
2024–2026 · grant · Standard Grant
SBIR Phase I: A computational framework to mitigate protein aggregation
Nicholas Rego · PDL BioPharma (United States) · funded by National Science Foundation
2020–2021 · cooperative agreement · U44
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)
Xin Jiang · PDL BioPharma (United States) · funded by National Institutes of Health
2020–2024 · cooperative agreement · U44
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)
Xin Jiang · PDL BioPharma (United States) · funded by National Institutes of Health
2020–2023 · cooperative agreement · U44
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)
Xin Jiang · PDL BioPharma (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses
Richard Labaudiniere · PDL BioPharma (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses
Richard Labaudiniere · PDL BioPharma (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Development of an early diagnostic and biomarker of treatment response for TTR amyloidoses (ATTR)
Xin Jiang · PDL BioPharma (United States) · funded by National Institutes of Health